Antineutrophil Cytoplasmic Antibody Positivity Is Associated with Vascular Involvement in Behçet’s Disease
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We investigated whether antineutrophil cytoplasmic antibody (ANCA) positivity is associated with vascular manifestationsat diagnosis of Behçet’s disease (BD) and poor outcomes during follow-up. Materials and Methods: We retrospectively reviewed the medical records of 1060 patients with BD. Among them, 808 patientscould be diagnosed with BD based on the revised version of the International Criteria for Behçet’s Disease (ICBD) in 2014 (2014ICBD criteria) and 588 patients could be diagnosed with BD based on the International Study Group (ISG) criteria proposed in1990 (1990 ISG criteria). We examined the sites and patterns of vascular involvement in the BD patients at diagnosis and evaluatedadverse outcomes during follow up, such as all-cause mortality, acute coronary syndrome, and deep vein thrombosis. Results: Among the 808 patients with BD based on the 2014 ICBD criteria, the rate of ANCA positivity at diagnosis was 2.2%. ANCA-positive BD patients exhibited a higher frequency of overall vascular manifestations (22.2% vs. 6.1%) and higher frequenciesof vascular involvement in the upper extremities and visceral arteries than ANCA-negative BD patients (5.6% vs. 0.1% and 5.6%vs. 0.1%). Among the 588 BD patients based on the 1990 ISG criteria, similarly, ANCA-positive BD patients exhibited a higher frequencyof vascular manifestations than ANCA-negative BD patients. ANCA positivity, however, did not seem to be associatedwith poor outcomes in BD patients during follow up. Conclusion: ANCA positivity in BD patients was found to be associated with cross-sectional vascular involvement in the upperextremities and visceral arteries at diagnosis but was not predictive of poor outcomes during follow-up.
Abstract
Purpose: We investigated whether antineutrophil cytoplasmic antibody (ANCA) positivity is associated with vascular manifestationsat diagnosis of Behçet’s disease (BD) and poor outcomes during follow-up. Materials and Methods: We retrospectively reviewed the medical records of 1060 patients with BD. Among them, 808 patientscould be diagnosed with BD based on the revised version of the International Criteria for Behçet’s Disease (ICBD) in 2014 (2014ICBD criteria) and 588 patients could be diagnosed with BD based on the International Study Group (ISG) criteria proposed in1990 (1990 ISG criteria). We examined the sites and patterns of vascular involvement in the BD patients at diagnosis and evaluatedadverse outcomes during follow up, such as all-cause mortality, acute coronary syndrome, and deep vein thrombosis. Results: Among the 808 patients with BD based on the 2014 ICBD criteria, the rate of ANCA positivity at diagnosis was 2.2%. ANCA-positive BD patients exhibited a higher frequency of overall vascular manifestations (22.2% vs. 6.1%) and higher frequenciesof vascular involvement in the upper extremities and visceral arteries than ANCA-negative BD patients (5.6% vs. 0.1% and 5.6%vs. 0.1%). Among the 588 BD patients based on the 1990 ISG criteria, similarly, ANCA-positive BD patients exhibited a higher frequencyof vascular manifestations than ANCA-negative BD patients. ANCA positivity, however, did not seem to be associatedwith poor outcomes in BD patients during follow up. Conclusion: ANCA positivity in BD patients was found to be associated with cross-sectional vascular involvement in the upperextremities and visceral arteries at diagnosis but was not predictive of poor outcomes during follow-up.
참고문헌 (18)
- Jennette JC, "2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides", Arthritis Rheum, 65, pp.1~11 (2013)
- Greco A, "Behçet’s disease : new insights into pathophysiology, clinical features and treatment options", Autoimmun Rev, 17, pp.567~575 (2018)
- Ambrose NL, "Differential diagnosis and management of Behçet syndrome", Nat Rev Rheumatol, 9, pp.79~89 (2013)
- International Study Group for Behçet’s Disease, "Criteria for diagnosis of Behçet’s disease", Lancet, 335, pp.1078~1080 (1990)
- International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD), "The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria", J Eur Acad Dermatol Venereol, 28, pp.338~347 (2014)
- Davatchi F, "The saga of diagnostic", classification criteria in Behcet’s disease, 2015, pp.18, 594~605
- Watts R, "Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies", Ann Rheum Dis, 66, pp.222~227 (2007)
- Millet A, "Antineutrophil cytoplasmic antibody-associated vasculitides:is it time to split up the group?", Ann Rheum Dis, 72, pp.1273~1279 (2013)
- Duzgun N, "Anti-neutrophil cytoplasmic antibody in Behçet’s disease", Int J Biomed Sci, 2, pp.49~52 (2006)
- Bossuyt X, "Position paper : revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis", Nat Rev Rheumatol, 13, pp.683~692 (2017)
- Tascilar K, "Vascular involvement in Behçet’s syndrome: a retrospective analysis of associations and the time course", Rheumatology(Oxford), 53, pp.2018~2022 (2014)
- Cocco G, "Cardiac pathology and modern therapeutic approach in Behçet disease", Cardiol J, 21, pp.105~114 (2014)
- Springer J, "Thrombosis in vasculitis", Curr Opin Rheumatol, 25, pp.19~25 (2013)
- Sasaki H, "A case of ANCA-associated large vessel vasculitis with multiple saccular aneurysms", J Rheumatol, 43, pp.179~ (2016)
- Satomura A, "Aortic aneurysm as a complication of myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis", Open Med(Wars), 12, pp.468~473 (2017)
- Chirinos JA, "Large vessel involvement in ANCA-associated vasculitides : report of a case and review of the literature", Clin Rheumatol, 23, pp.152~159 (2004)
- Kang A, "High incidence of arterial and venous thrombosis in antineutrophil cytoplasmic antibody-associated vasculitis", J Rheumatol, 46, pp.285~293 (2019)
- McAdoo SP, "Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis", Nephrol Dial Transplant, 34, pp.63~73 (2019)